Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141917

Published: 2020

Journal Articles

Selective Targeting of Alternative Splicing Deregulation in Pediatric Acute Myeloid Stem and Progenitor Cells

Inge Van Der Werf, MSc, Phoebe Mondala, BS, Raymond Diep, BS, Larissa Balaian, PhD, Cayla Mason, BS, Jacqueline Cloos, PhD, Gertjan J.L. Kaspers, Prof. MD PhD, Jim La Clair, Peggy Wentworth, Leslie A Crews, PhD, Thomas Whisenant, PhD, Kathleen Fisch, PhD, Michael Burkart, PhD, Catriona Jamieson, MD PhD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-136596

Published: 2020

Journal Articles

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

Benjamin Heyman, MD, Michael Y. Choi, MD, Emanuela M. Ghia, PhD, George F. Widhopf II, PhD, Minya Pu, PhD, Emily Pittman, PhD, Karen Messer, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-134711

Published: 2020

Journal Articles

Imetelstat Inhibits Telomerase and Prevents Propagation of ADAR1-Activated Myeloproliferative Neoplasm and Leukemia Stem Cells

Wenxue Ma, MD PhD, Larissa Balaian, PhD, Phoebe Mondala, BS, Yudou He, BS, Cayla Mason, BS, Jessica Pham, B.S., Jeremy Lee, BS, Raymond Diep, BS, Sanja Coso, PhD, Kathleen Fisch, PhD, Adam Mark, MS, Sheldon Morris, MD MPH, Qingfei Jiang, PhD, Thomas Whisenant, PhD, Aleksandra Rizo, MD PhD, Fei Huang, PhD, Mary Donohoe, PhD, Ludmil Alexandrov, PhD, Catriona Jamieson, MD PhD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-140771

Published: 2020

Journal Articles

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Michael Y. Choi, MD, Emanuela M. Ghia, PhD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Hun Ju Lee, Jacqueline C. Barrientos, MD MS, Nicole Lamanna, MD, Alec Goldenberg, Dimitrios Tzachanis, MD PhD, Erin G. Reid, MD MS, Elizabeth K Weihe, MD, Laura Z. Rassenti, PhD, Iris Isufi, MD, Stewart Bieler, BA, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2019) 134 (Supplement_1): 1755.

https://doi.org/10.1182/blood-2019-131498

Published: 2019

Journal Articles

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

Claire N Harrison, Professor, Jacqueline S Garcia, MD, Ruben A Mesa, MD, Tim CP Somervaille, MD PhD, Rami S. Komrokji, MD, Naveen Pemmaraju, MD, Catriona Jamieson, MD PhD, Nikolaos Papadantonakis, MDPhDMSc, James M. Foran, MD, Casey L. O'Connell, MD, Leanne Holes, BS, MBA,, Jia Jia, PhD MBA, Jason Harb, PhD, Jessica Hutti, PhD, Josef T. Prchal, MD

Blood (2019) 134 (Supplement_1): 671.

https://doi.org/10.1182/blood-2019-130158

Published: 2019

Journal Articles

A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity

Blood (2019) 134 (Supplement_1): 4141.

https://doi.org/10.1182/blood-2019-131113

Published: 2019

Journal Articles

Inflammatory Cytokine Responsive Enzymatic Mutagenesis Fuels Myeloproliferative Neoplasm Pre-Leukemia Stem Cell Evolution

Catriona Jamieson, MD PhD, Qingfei Jiang, PhD, Frida Holm, PhD, Jane Isquith, MS, Adam Mark, Cayla Mason, BS, Wenxue Ma, MD PhD, Raymond H Diep, Jessica Pham, B.S., Eduardo Reynoso Moreno, PhD, Chanond A Nasamran, Xu Guorong, Amanda Birmingham, Leslie A Crews, PhD, Ludmil Alexandrov, Gabriel Pineda, PhD, Thomas Whisenant, Kathleen M Fisch

Blood (2019) 134 (Supplement_1): 3780.

https://doi.org/10.1182/blood-2019-131510

Published: 2019

Journal Articles

RNA Editing of Tumor Suppressor Mir-26a Promotes Malignant Progenitor Propagation in Chronic Myeloid Leukemia

Raymond H Diep, Qingfei Jiang, PhD, Jane Isquith, MS, Maria A. Zipeto, PhD, Jessica Pham, Nathan Delos Santos, BS, Julisia Chau, B.S., Sheldon Morris, MD MPH, Catriona Jamieson, MD PhD

Blood (2018) 132 (Supplement 1): 2611.

https://doi.org/10.1182/blood-2018-99-116988

Published: 2018

Journal Articles

Comparative Inflammasome Analysis of Bone Marrow Stroma in Aging and Myelofibrosis

Larissa Balaian, PhD, Leslie A Crews, PhD, Cayla Mayson, BS, Frida Holm, PhD, Raymond H Diep, Heather Leu, BS, Anna Kulidjian, MD, Edward D. Ball, MD, Catriona Jamieson, MD PhD

Blood (2018) 132 (Supplement 1): 4331.

https://doi.org/10.1182/blood-2018-99-118993

Published: 2018

Journal Articles

Genomic Sequencing Reveals Complex and Actionable Molecular Profiles across Hematologic Malignancies

Natalie Galanina, MD, Catriona Jamieson, MD PhD, Razelle Kurzrock, MD

Blood (2018) 132 (Supplement 1): 5116.

https://doi.org/10.1182/blood-2018-99-119877

Published: 2018

Journal Articles

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

Yun Chen, PhD, Michael Y. Choi, MD, Liguang Chen, PhD, Jian Yu, PhD, Ling Zhang, Emanuela M. Ghia, PhD, Elsa Sanchez-Lopez, PhD, George F. Widhopf II, PhD, Karen Messer, PhD, Laura Z. Rassenti, PhD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD

Blood (2018) 132 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2018-99-111996

Published: 2018

Journal Articles

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Jorge E. Cortes, MD, Cristina Papayannidis, Catriona Jamieson, MD PhD, Gary J. Schiller, MD, Anna Candoni, MD, Brian Leber, MD, Claudia D. Baldus, MD, José A. Pérez-Simón, MD PhD, Weidong Wendy Ma, Corrado Gallo Stampino, Ashleigh O'Connell, Mirjana Zeremski, MD, Geoffrey Chan, MD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2018-99-110934

Published: 2018

Journal Articles

Biomarkers of Overall Survival and Response to Glasdegib and Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia

Jorge E. Cortes, MD, Akil Merchant, MD, Catriona Jamieson, MD PhD, Daniel A Pollyea, MD, Michael Heuser, MD, Geoffrey Chan, MD, Panpan Wang, Keith A Ching, Jillian Johnson, Thomas O'Brien

Blood (2018) 132 (Supplement 1): 2733.

https://doi.org/10.1182/blood-2018-99-111239

Published: 2018

Journal Articles

Genetic Modulation of Adenosine-to-Inosine RNA Editing Selectively Disrupts Inflammasome and Extracellular Matrix Genes in Multiple Myeloma

Leslie A Crews, PhD, Phoebe Mondala, BS, Elisa Lazzari, PhD, Gabriel Pineda, PhD, Christina Wu, PhD, Caitlin L. Costello, MD, Catriona Jamieson, MD PhD

Blood (2018) 132 (Supplement 1): 1324.

https://doi.org/10.1182/blood-2018-99-120326

Published: 2018

Journal Articles

Hippo Kinase Inactivation Contributes to Del(20q) Malignancies and Cooperates with JAK2-V617F to Promote Myelofibrosis in Mice

Samuel A Stoner, Ming Yan, PhD, Katherine Liu, Takahiro Shima, MD PhD, Huan-You Wang, MD PhD, Kei-Ichiro Arimoto, PhD, Rafael Bejar, MD PhD, Catriona Jamieson, MD PhD, Kun-Liang Guan, PhD, Dong-Er Zhang, PhD

Blood (2018) 132 (Supplement 1): 99.

https://doi.org/10.1182/blood-2018-99-115591

Published: 2018

Journal Articles

ADAR1-MediatedGLI1 Editing Promotes Malignant Self-Renewal in Multiple Myeloma

Leslie Crews, PhD, Elisa Lazzari, PhD, Phoebe Mondala, BS, Nathan Delos Santos, BS, Amber Miller, PhD BA, Gabriel Pineda, PhD, Qingfei Jiang, PhD, Heather Leu, BS, Shawn Ali, BA, Anusha Preethi Ganesan, MD PhD, Christina Wu, PhD, Caitlin L. Costello, MD, Mark D. Minden, MD PhD, Raffaella Chiaramonte, PhD, A. Keith Stewart, MBChB, MBA, Catriona Jamieson, MD PhD

Blood (2017) 130 (Supplement 1): 1204.

https://doi.org/10.1182/blood.V130.Suppl_1.1204.1204

Published: 2017

Journal Articles

Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab

Michael Choi, MD, George F. Widhopf II, PhD, Jian Yu, PhD, Liguang Chen, PhD, Md. Kamrul Hasan, PhD, Laura Z. Rassenti, PhD, Emily Pittman, PhD, Karen Messer, PhD, Charlene Gutierrez, BS, Reilly Lilianna Kidwell, BSc, Charles E. Prussak, PharmD, PhD, Januario E Castro, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD

Blood (2017) 130 (Supplement 1): 829.

https://doi.org/10.1182/blood.V130.Suppl_1.829.829

Published: 2017

Journal Articles

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Blood (2017) 130 (Supplement 1): 45.

https://doi.org/10.1182/blood.V130.Suppl_1.45.45

Published: 2017

Journal Articles

Case Series of Potential Wernicke's Encephalopathy in Patients Treated with Fedratinib

Claire N. Harrison, BMBCh, DM, FRCP, FRCPath, Ruben A Mesa, MD, Catriona Jamieson, MD PhD, John Hood, PhD, Julie Bykowski, MD, Giulio Zuccoli, MD, James Brewer, MD,PhD

Blood (2017) 130 (Supplement 1): 4197.

https://doi.org/10.1182/blood.V130.Suppl_1.4197.4197

Published: 2017

NARROW

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Selective Targeting of Alternative Splicing Deregulation in Pediatric Acute Myeloid Stem and Progenitor Cells

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

Imetelstat Inhibits Telomerase and Prevents Propagation of ADAR1-Activated Myeloproliferative Neoplasm and Leukemia Stem Cells

Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity

Inflammatory Cytokine Responsive Enzymatic Mutagenesis Fuels Myeloproliferative Neoplasm Pre-Leukemia Stem Cell Evolution

RNA Editing of Tumor Suppressor Mir-26a Promotes Malignant Progenitor Propagation in Chronic Myeloid Leukemia

Comparative Inflammasome Analysis of Bone Marrow Stroma in Aging and Myelofibrosis

Genomic Sequencing Reveals Complex and Actionable Molecular Profiles across Hematologic Malignancies

Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

Glasdegib in Addition to Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia: Safety Analysis of Glasdegib 'On Target' Adverse Events

Biomarkers of Overall Survival and Response to Glasdegib and Intensive or Non-Intensive Chemotherapy in Patients with Acute Myeloid Leukemia

Genetic Modulation of Adenosine-to-Inosine RNA Editing Selectively Disrupts Inflammasome and Extracellular Matrix Genes in Multiple Myeloma

Hippo Kinase Inactivation Contributes to Del(20q) Malignancies and Cooperates with JAK2-V617F to Promote Myelofibrosis in Mice

ADAR1-MediatedGLI1 Editing Promotes Malignant Self-Renewal in Multiple Myeloma

Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab

The Bone Marrow Niche Uses Mir-300 As a Biological Rheostat to Selectively Control Stem Cell-Driven Malignant Hematopoiesis and Innate Anti-Cancer Immunity

Case Series of Potential Wernicke's Encephalopathy in Patients Treated with Fedratinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only